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     * Honorable John R. Gibson, United States Court of Appeals for the Eighth Circuit,
sitting by designation.
NOT PRECEDENTIAL
UNITED STATES COURT OF APPEALS
FOR THE THIRD CIRCUIT
            
No. 05-4566
            
GLAXOSMITHKLINE CONSUMER HEALTHCARE, L.P.
   v.
MERIX PHARMACEUTICAL CORP.,
Appellant
          
On Appeal from the United States District Court
for the District of New Jersey
(D.C. Civil No. 05-cv-00898)
District Court Judge: Honorable Dickinson R. Debevoise
         
Submitted pursuant to Third Circuit L.A.R. 34.1(a)
June 29, 2006
Before: BARRY, VAN ANTWERPEN and JOHN R. GIBSON,* Circuit Judges.
(Filed:  June 29, 2006)
         
OPINION OF THE COURT
         
VAN ANTWERPEN, Circuit Judge.
Appellant Merix Pharmaceutical Corporation (“Merix”), defendant below, brings
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this interlocutory appeal to challenge the preliminary injunction entered against it
following the motion of plaintiff-appellee GlaxoSmithKline Consumer Healthcare, L.P.
(“Glaxo”).  Glaxo sought the preliminary injunction incident to its lawsuit against Merix
for false advertising under § 43(a) of the Lanham Act, 15 U.S.C. § 1125(a), and the New
Jersey Consumer Fraud Act, N.J.S.A. § 56:8-2.  The District Court granted the injunction,
and for the reasons set forth herein, we will affirm.
I.
Because we write only for the parties, our discussion of the facts is limited to those
necessary to adjudication of the case.  Glaxo produces and markets a number of over the
counter (“OTC”) pharmaceuticals, including Abreva.  Abreva is an FDA-approved, non-
prescription medication that shortens the duration of the healing time for cold sores.  It
has been publicly available since late 2000, and retails for roughly $15 to $18 a tube. 
Merix markets its cold sore product, Releev, online and in drug stores for roughly $15 to
$20 a tube.  Drug stores often stock Releev adjacent to or nearby Abreva.
Meryl Squires formed Merix after discovering that a blend of a common topical
antiseptic, benzalkonium chloride and the herb Echinacea relieved the symptoms of the
cold sores she frequently suffered.  Her friends who tried the compound agreed that it was
helpful.  She obtained two patents on the substance, and ultimately marketed it as Releev. 
Merix is a small company, with a total of four employees.  Merix started out selling
Releev on the internet, and in June 2003, began retailing it in national drug store chains
where it competed directly with Abreva.  Merix’s annual revenues have recently run to
several million dollars.
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Glaxo brought the instant suit against Merix because it believed the claims Merix
made about Releev were false and misleading, and Releev would thereby unfairly
compete with Abreva.  This is not the first time Glaxo challenged Merix’s claims about
Releev.  In 2003, Glaxo informed the FDA of the claims, which resulted in the agency
sending a warning letter to Merix.  In July 2004, Glaxo brought an advertising challenge
against Merix before the National Advertising Division (“NAD”) of the Better Business
Bureau.  Participation in NAD proceedings is voluntary, and the results are non-binding. 
Merix participated.  The NAD found in favor of Glaxo on all issues presented; Merix
appealed to the NAD Review Board.  Glaxo abandoned the proceedings there and
commenced the present action on February 16, 2005 in the United States District Court
for the District of New Jersey.
As set forth by the District Court, Glaxo challenged, and sought a preliminary
injunction against, a number of Merix’s claims, including, inter alia:
“1.  Releev has been “clinically proven”: (a) to be a “1 Day Cold Sore
Treatment” and (b) to “prevent outbreaks”[;]
2.  Releev is endorsed by the University of Chicago;
3.  Clinical research by Releev’s Principal Clinical Investigator has been
published;
4.  Releev uses the product name Vira Medx;
5.  The Releev package bears “before and after” photographs purportedly
showing marked improvement after 1 day, after 3 days, and after 5 days.”
App. 5.  At the inception of the preliminary injunction hearing, counsel for Merix
reported that Merix had altered its packaging and promotional material to remove the
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problematic claims, and pressed that Glaxo’s motion for injunctive relief be denied as
moot.  Its new claims, modified in time for the preliminary injunction hearing, consist of
redesigned packaging that asserts:
“1 Day Cold Sore Treatment
Relieves Symptoms in Just a Day!”
Supp. App. 198.  The top line is displayed in a more prominent typeface than the second. 
The packaging also offers “before and after” photos on the back.  The prospective
purchaser is referred to them by an exhortation on the front of the package to “See actual
Before and After Photos on back panel.”  Three photos show a cold sore at one, three, and
five days; it is progressively improved.
The District Court concluded that both sets of claims – those prior to the
preliminary injunction proceedings, and those made as a result of their institution –  were
false.  Indeed, it found that “[t]he only claim that Merix can truthfully make for RELEEV
is that it provides relief from cold sore symptoms.” App. 14 (emphasis added).  It
concluded that the new set of claims still implied a cure by characterizing Releev as a “1
Day . . . Treatment” and showing before and after photos indicating Releev speeds
healing rather than merely relieving symptoms.  Without belaboring the point, Merix has
essentially conceded, for purposes of proceedings on the preliminary injunction, that it
could not prevail in its defense of its product claims.
With respect to the preliminary injunction, the District Court concluded that Glaxo
had proved its case.  The Court found that Glaxo had a high likelihood of success on the
merits where it would have to prove that the claims violated § 43(a) of the Lanham Act,
     1 The elements of a Lanham Act claim for false advertising are:
“1) that the defendant has made false or misleading statements
as to his own product [or another’s]; 2) that there is actual
deception or at least a tendency to deceive a substantial
portion of the intended audience; 3) that the deception is
material in that it is likely to influence purchasing decisions;
4) that the advertised goods traveled in interstate commerce;
and 5) that there is a likelihood of injury to the plaintiff in
terms of declining sales, loss of good will, etc.”
Ditri v. Coldwell Banker Residential Affiliates, Inc., 954 F.2d 869, 872 (3d Cir. 1992)
(quoting U.S. Healthcare v. Blue Cross of Greater Phila., 898 F.2d 914, 922-23 (3d Cir.
1990)).
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15 U.S.C. § 1125(a).1  The District Court also concluded that Glaxo would suffer
irreparable harm absent the injunction.  In particular, the Court concluded that Releev and
Abreeva competed head-to-head because they were the only two cold sore products
selling in the $15 to $20 range, and stores placed them on shelves in close proximity to
each other.  Accordingly, given the unanswered testimony of Glaxo Vice President
Jeffrey Brown, Glaxo had lost, and would continue to lose, sales to Releev because of
Merix’s false advertising.  Furthermore, when customers found that Releev did not live
up to its promises, its failures might also tar the reputation and goodwill of Abreva, which
is the only other cold sore product in the same price range.  To the extent the failure to
seek interlocutory relief as soon as absolutely practicable weighs against a finding of
irreparable harm, the District Court concluded that Glaxo should not have been faulted for
initially attempting to resolve its dispute by gentler means.  The District Court went on to
complete its preliminary injunction analysis, holding that the injury to Merix of granting
it did not outweigh the injury to Glaxo of withholding it, and that prevention of false
     2 The parties do not dispute the District Court’s findings on these latter two issues, and
we do not review them.
     3 The test for a preliminary injunction requires the district court to consider four now-
familiar factors:
“(1) whether the movant has shown a reasonable probability of success on
the merits; (2) whether the movant will be irreparably injured by denial of
the relief; (3) whether granting preliminary relief will result in even greater
harm to the nonmoving party; and (4) whether granting the preliminary
relief will be in the public interest.”
Am. Civil Liberties Union of N.J. v. Black Horse Pike, 84 F.3d 1471, 1477 n.2 (3d Cir.
1996) (citations and quotations omitted).  We review orders granting or denying
preliminary injunctions for abuse of discretion, but examine the underlying findings of
fact for clear error and afford plenary review to questions of law.  Doe v. National Bd. of
Medical Examiners, 199 F.3d 146, 154 (3d Cir. 1999).
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advertising and promotion of lawful competition would serve the public interest.2
II.
The District Court had jurisdiction under 28 U.S.C. §§ 1331 and 1367.  We have
jurisdiction to review grants or denials of preliminary injunctions as interlocutory matters
pursuant to 28 U.S.C. § 1292(a)(1).3  Examining the District Court’s findings of fact,
conclusions of law, and analysis, we discern neither error nor abuse of discretion.  We
will affirm for essentially the same reasons set forth by the learned Court in its September
13, 2005 opinion and order, and therefore do not recapitulate its analysis here.
We have only the following to add.  The parties make much of the evidence
adduced by Glaxo to support its claim of irreparable harm.  Among other things, Merix
argues both that it is speculative, and shows no injury that post hoc damages could not
redress.  Assuming, without deciding, that this evidence was less than optimal, we briefly
note two points.  First, Merix points to no evidence to rebut the testimony of Brown that
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Merix’s false advertising about Releev would damage divert sales of Abreva.  The
District Court was justified in relying on it, and we discern no clear error in its factual
finding in this respect; that is, we are not “left with the definite and firm conviction that a
mistake has been committed.”  Anderson v. Bessemer City, 470 U.S. 564, 573 (1985); see
United States v. Westinghouse Elec. Corp., 788 F.2d 164, 169 (3d Cir. 1986) (no clear
error where court relied on unrebutted testimony).
Second, any other result would set an unworkably high bar for a district court’s
fact finding under these circumstances. Given the time-is-of-the-essence nature of
preliminary injunction proceedings, courts and parties cannot develop the same depth in
the factual record they can at trial.  See U.S. Steel Corp. v. Fraternal Ass’n of
Steelhaulers, 431 F.2d 1046, 1048 (3d Cir. 1970). “[T]he grant or denial of a preliminary
injunction is almost always based on an abbreviated set of facts, requiring a delicate
balancing of the probabilities of ultimate success at final hearing with the consequences
of immediate irreparable injury.”  Id.  In deciding a motion for a preliminary injunction, a
district court must weigh the appropriate factors, rather than mechanically apply them. 
See id. (“delicate balancing”); Gerardi v. Pelullo, 16 F.3d 1363, 1373 (3d Cir. 1994).
Here, there is no denying the formidable strength of Glaxo’s merits case.  Merix
concedes as much for purposes of this appeal in its summary of its argument in its brief. 
Br. of Appellant at 14.  The District Court has made adequate – and uncontroverted –
findings on the issue of irreparable injury to support its conclusion, and it properly
considered and balanced those concerns pertinent to the interlocutory relief requested by
Glaxo. Accordingly, the District Court did not abuse its discretion in issuing the
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preliminary injunction.
III.
As just discussed, we will affirm for the reasons set forth herein and in the
September 13, 2005 opinion of the District Court.
